ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Myfembree as the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 27, 2021MYOV and Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for the management of heavy menstrual bleeding
Pharma Sources Insight January 2025
